Pfizer Inc. $PFE Position Trimmed by Lincluden Management Ltd.

Lincluden Management Ltd. decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 0.5% in the 2nd quarter, Holdings Channel reports. The firm owned 413,558 shares of the biopharmaceutical company’s stock after selling 1,896 shares during the quarter. Pfizer comprises about 1.1% of Lincluden Management Ltd.’s investment portfolio, making the stock its 22nd biggest holding. Lincluden Management Ltd.’s holdings in Pfizer were worth $10,025,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in PFE. Pacer Advisors Inc. increased its stake in Pfizer by 856.8% during the first quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company’s stock valued at $508,164,000 after purchasing an additional 17,957,928 shares during the last quarter. Amundi increased its stake in Pfizer by 43.4% during the first quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock valued at $1,265,277,000 after purchasing an additional 15,758,846 shares during the last quarter. Nuveen LLC bought a new stake in Pfizer during the first quarter valued at $389,861,000. Goldman Sachs Group Inc. increased its stake in Pfizer by 51.9% during the first quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company’s stock valued at $670,407,000 after purchasing an additional 9,041,990 shares during the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of Pfizer by 0.9% during the first quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company’s stock valued at $13,257,004,000 after acquiring an additional 4,629,976 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

PFE stock opened at $24.81 on Friday. The company has a market capitalization of $141.03 billion, a P/E ratio of 13.19, a PEG ratio of 0.81 and a beta of 0.55. The company has a 50-day simple moving average of $24.86 and a 200 day simple moving average of $24.13. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $29.82. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same period in the prior year, the company earned $0.60 EPS. Pfizer’s revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. Pfizer’s dividend payout ratio is currently 91.49%.

Analysts Set New Price Targets

Several brokerages have recently issued reports on PFE. Citigroup boosted their price target on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Morgan Stanley reduced their price target on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a report on Friday. Bank of America boosted their price target on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a report on Wednesday. Finally, UBS Group reissued a “neutral” rating and set a $28.00 price target on shares of Pfizer in a report on Wednesday, October 1st. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $28.35.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.